Expanded Access Program of AMTAGVI That is Out of Specification for Commercial Release
Latest Information Update: 30 Mar 2025
At a glance
- Drugs Lifileucel (Primary)
- Indications Malignant melanoma
- Focus Expanded access; Therapeutic Use
- Sponsors Iovance Biotherapeutics
- 09 Oct 2023 Status changed from recruiting to completed.
- 06 Jun 2022 New trial record